Advertisement
YOU ARE HERE: LAT HomeCollectionsAllergan

Business Briefing / Pharmaceuticals

Allergan eyelash drug ads censured

September 17, 2009|Times Wire Reports

Allergan Inc.'s promotions for the eyelash-growing drug Latisse are "misleading" because they don't describe safety risks, regulators said.

The Food and Drug Administration cited the website www.latisse.com and a placard with a timeline of the product's introduction in a warning letter to the Irvine company.

Allergan says the timeline is no longer being used.

Materials promoting a drug's benefits must also address its risks, which in this case include allergic reactions or hair growth outside the treatment area, the FDA said.

Advertisement
Los Angeles Times Articles
|
|
|